High affinity monoclonal antibody targeting Siglec-15 for cancer immunotherapy
Background and Aim: Recently, Siglec-15 has been proved as a novel immune suppressor and a potential target for normalization cancer immunotherapy, which is non-redundant to the well-known PD-L1/PD-1 pathway. Herein, anti-Siglec-15 mAb, a monoclonal antibody (mAb) with a high affinity against Siglec-15, was prepared.
Methods: The engineered CHO-K1 Siglec-15 cell line was constructed to heterologously expressed Siglec-15 for the affinity test with the mAb. Antigens Siglec-15-mIgG and Siglec-15-his were recombinantly expressed by 293F cells and purified by high-performance liquid chromatography (HPLC). Hybridoma cell line against Siglec-15 was prepared and validated by enzyme-linked immunoabsorbant assay (ELISA) and fluorescent-activated cell sorting (FACS). Finally, the antiSiglec-15 mAb was produced, purified, and confirmed by SDS-PAGE, ELISA, and FACS.
Results: The EC50 of the anti-Siglec-15 mAb with Siglec-15 is 76.65 ng/mL, lower than that of the positive control 5G12 (90.7 ng/mL), indicating a high affinity of the anti-Siglec-15 mAb. In vitro and in vivo studies verified that the anti-Siglec-15 mAb blocks the Siglec-15-mediated suppression of T cell and moderately prevents the tumor growth.
Conclusions: The anti-Siglec-15 mAb can be considered as an effective immunotherapy for tumor suppression.
Relevance for Patients: The anti-Siglec-15 mAb prepared in this study is useful as an immune checkpoint inhibitor against Siglec-15 for normalization cancer immunotherapy. This immunotherapy provides an alternative treatment for cancer patients who are refractory to the well-known PD-L1/PD-1-targeting therapies.
[1] Friederike L, Heiko G, Sørge K, Frank D, Evolution of Sialic Acid-Binding Proteins: Molecular Cloning and Expression of Fish Siglec-4. Glycobiology 2004;14:959- 68.
[2] Schauer R. Sialic Acids: Fascinating Sugars in Higher Animals and Man. Zoology (Jena) 2004;107:49-64.
[3] Crocker PR, Paulson JC, Varki A, Siglecs and Their Roles in the Immune System. Nat Rev Immunol 2007;7:255-66.
[4] Takashi A, Ajit V. Chemical Diversity in the Sialic Acids and Related α-Keto Acids: An Evolutionary Perspective. Chem Rev 2002;102:439-69.
[5] Varki A, Angata T. Siglecs-the Major Subfamily of I-Type Lectins. Glycobiology 2006;16:1R-27R.
[6] Bornhofft KF, Goldammer T, Rebl A, Galuska SP. Siglecs: A Journey Through the Evolution of Sialic Acid-Binding Immunoglobulin-Type Lectins. Dev Comp Immunol 2018;86:219-31.
[7] Angata T, Tabuchi Y, Nakamura K, Nakamura M. Siglec-15: An Immune System Siglec Conserved Throughout Vertebrate Evolution. Glycobiology 2007;17:838-46.
[8] Crocker PR, Redelinghuys P. Siglecs as Positive and Negative Regulators of the Immune System. Biochem Soc Trans 2008;36:1467-71.
[9] O’Reilly MK, Paulson JC, Siglecs as Targets for Therapy in Immune-Cell-Mediated Disease. Trends Pharmacol Sci 2009;30:240-8.
[10] Pillai S, Netravali IA, Cariappa A, Mattoo H. Siglecs and immune regulation. Annu Rev Immunol 2012;30:357-92.
[11] Macauley MS, Crocker PR, Paulson JC. Siglec-Mediated Regulation of Immune Cell Function in Disease. Nat Rev Immunol 2014;14:653-66.
[12] Stuible M, Moraitis A, Fortin A, Saragosa S, Kalbakji A, Filion M, et al. Mechanism and Function of Monoclonal Antibodies Targeting Siglec-15 for Therapeutic Inhibition of Osteoclastic Bone Resorption. J Biol Chem 2014;289:6498-512.
[13] Hiruma Y, Hirai T, Tsuda E. Siglec-15, a Member of the Sialic Acid-Binding Lectin, is a Novel Regulator for Osteoclast Differentiation. Biochem Biophys Res Commun 2011;409:424-9.
[14] Angata T. Siglec-15: A Potential Regulator of Osteoporosis, Cancer, and Infectious Diseases. J Biomed Sci 2020;27:1-7.
[15] Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, et al. Siglec-15 as an Immune Suppressor and Potential Target for Normalization Cancer Immunotherapy. Nat Med 2019;25:656-66.
[16] Rina T, Kazuaki O, Shinji T, Naoyuki T, Takashi A. The Interaction between Siglec-15 and Tumor-Associated Sialyl-Tn Antigen Enhances TGF-Secretion from Monocytes/Macrophages through the DAP12-Syk
Pathway. Glycobiology 2013;23:178-87.
[17] Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 2018;175:313-26.
[18] Rina T, Kazuaki O, Shinji T, Naoyuki T, Takashi A. The Interaction between Siglec-15 and Tumor-Associated Sialyl-Tn Antigen Enhances TGF-β Secretion from Monocytes/Macrophages through the DAP12-Syk
Pathway. Glycobiology 2012;23:178-87.
[19] Yung-Chi C, Victor N. The Interplay between Siglecs and Sialylated Pathogens. Glycobiology 2014;24:818-25.
[20] Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer Immunotherapies Targeting the PD-1 Signaling Pathway. J Biomed Sci 2017;24:26.
[21] Ribas A, Hu-Lieskovan S. What does PD-L1 Positive or Negative Mean? J Exp Med 2016;213:2835-40.
[22] Guangchao C, Zhiqiang X, Zhinan Y. Normalization Cancer Immunotherapy: Blocking Siglec-15! Signal Transduct Target Ther 2019;4:10.
[23] Ling S, Xiao S, Xie C, Wang R, Zeng L, Wang K, et al. Preparation of Monoclonal Antibody for Brevetoxin 1 and Development of Ic-ELISA and Colloidal Gold Strip to Detect Brevetoxin 1. Toxins 2018;10:75-86.
[24] Saeed A, Ling S, Yuan J, Wang S. The Preparation and Identification of a Monoclonal Antibody against Domoic Acid and Establishment of Detection by Indirect Competitive ELISA. Toxins 2017;9:250-66.
[25] Nikolayenko IV, Galkin OY, Grabchenko NI, Spivak MY. Preparation of Highly Purified Human IgG, IgM, and IgA for Immunization and Immunoanalysis. Ukr Bioorg Acta 2005;2:3-11.